1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Respite Ministries or Programs Grant is sponsored by Tennessee Department of Disability and Aging. The Department is providing one-time funding to faith-based 501(c)(3) nonprofit organizations to create respite ministries or programs. These programs should offer a safe place of rest for people with intellectual and developmental disabilities and their families.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Faith-based 501(c)(3) nonprofit organizations. Confirm the full requirements in the official notice before applying.
The current listing shows up to $25,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Respite Ministries or Programs Grant is funded by Tennessee Department of Disability and Aging. Verify program details on the funder's official page before applying.
This opportunity targets applicants in Tennessee. If your organization operates elsewhere, check the official notice for location requirements.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Tennessee's $206.9M RHTP allocation begins distribution with a 30-day virtual maternal/child mental health consultation grant. The state plans a new opportunity every Friday — the cadence and structure here are the blueprint for how the $50B nationwide program rolls out.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article